Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Novo Nordisk will pay $300M upfront for exclusive rights to HRS-1596 outside mainland China, Hong Kong, Macao and Taiwan, in a deal valued up to $2.6B. The phase 1-ready dual GLP-1/GIP agonist targets weight management and type 2 diabetes, with potential once-weekly oral dosing. Additional milestone and sales payments
Novo Nordisk gets exclusive rights outside mainland China, Hong Kong, Macau and Taiwan. Hengrui will receive $300 million upfront plus milestones and royalties; closing is expected in Q4 2026, subject to U.S. antitrust clearance and other conditions.